Blue Flower

Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

Dear Madam, Dear Sir

On behalf of the entire NOXXON team I am pleased to welcome you to this section of our website. NOXXON is a European biopharmaceutical company developing anticancer treatments targeting the tumor microenvironment quoted on Euronext Growth - Paris, formerly Alternext.

Our goal is to significantly improve cancer therapies, including immuno-oncology approaches, such as checkpoint inhibitors, and standard therapies such as chemo- and radio-therapy.

In December 2018, the company reported top-line data from the clinical trial of the combination of NOX A12 with Keytruda® in heavily pre-treated metastatic micro-satellite stable pancreatic and colorectal cancer patients. These data demonstrated that NOX-A12, in monotherapy, penetrates the tumor tissue where it neutralizes its target and can stimulate an increased immune response within the tumor, making the tumor microenvironment immunologically “hotter”. In the second part of the study, when NOX-A12 was then combined with Merck’s anti-PD-1 immunotherapeutic antibody, Keytruda®, 25% of patients achieved stable disease according to the iRECIST criteria, despite 95% of all patients having a best response of progressive disease to their prior anti-cancer treatment. Furthermore, 35% of patients had prolonged time on therapy, relative to their prior treatment. As such, we believe that further work in both tumor types is warranted for NOX-A12.

We have announced that the company had initiated preparations to test the combination of NOX-A12 + radiotherapy in brain cancer patients, with the aim to initiate the trial in Q2-2019. The combination strategy of NOX-A12 + radiotherapy is supported by strong preclinical data and top-level academics in both the US and Europe (see the presentation from our September 2018 brain cancer KOL event here: Link).
NOX-E36 is a Phase 2 ready asset for the treatment of cancer and recent preclinical data shows activity of this compound in a second solid tumor indication, liver cancer. This complements initial data in a pancreatic cancer model.

We are pleased to count you amongst our shareholders at this pivotal stage in our development as a company and we will continue to work on enhancing the therapeutic impact of anti-cancer therapies by combining them with our compounds NOX-A12 and NOX-E36.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer

• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities


L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017